Linda Sylvester

  • Citations Per Year
Learn More
PURPOSE The aim of this study was to evaluate the efficacy and toxicity of imatinib, a platelet-derived growth factor-beta receptor antagonist, when added to the combination bevacizumab/erlotinib in the treatment of patients with advanced clear cell renal carcinoma. PATIENTS AND METHODS Ninety-four patients with metastatic clear cell renal carcinoma were(More)
Freemartins are XX/XY chimaeras that develop as a result of the fusion of the placental circulation of at least one male and one female fetus. The pituitary glands of eight normal ewes at various stages of the oestrous cycle and three rams were compared with those of two male-type and three undifferentiated-type freemartins. The pituitaries were heaviest in(More)
Freemartins are XX/XY chimaeras that develop as a result of the fusion of the placental circulation of at least one male and one female fetus. Of 19 freemartin ewes, 13 had testis-like structures, seven of them in an abdominal position and six in an inguinal position. Histologically, their gonads had structures resembling seminiferous tubules and(More)
PURPOSE To evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and etoposide in the first-line treatment of patients with stage III or IV adenocarcinoma of the ovary. PATIENTS AND METHODS Patients entering this trial received paclitaxel 200 mg/m(2), 1 h IV infusion, day 1; carboplatin AUC 6.0 IV, day 1; etoposide 50 mg(More)
7275 Background: Topotecan given intravenously for 5 consecutive days every 3 weeks is standard second-line therapy for patients (pts) with relapsed small cell lung cancer (SCLC) and ovarian cancer. Weekly bolus topotecan produces significantly less toxicity than the 5 day schedule, and appears as active as the standard schedule in pts with relapsed ovarian(More)
  • 1